Aclaris Therapeutics (ACRS) Net Income towards Common Stockholders (2014 - 2026)

Aclaris Therapeutics' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$37.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 102.61% year-over-year to -$37.5 million in Q1 2026; TTM through Mar 2026 was -$106.8 million, a 27.77% increase from a year earlier, with the FY2025 full-year figure at -$273.0 million, down 106.7% from the prior year.
• Net Income towards Common Stockholders retreated to -$37.5 million in Q1 2026 per ACRS's latest filing, from -$31.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$1.9 million in Q4 2023 and bottomed at -$213.2 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$32.2 million (2022), against an average of -$41.2 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 99.12% in 2023 and sank 5684.72% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$213.2 million in 2022, then soared by 99.12% to -$1.9 million in 2023, then sank by 5684.72% to -$108.3 million in 2024, then surged by 71.08% to -$31.3 million in 2025, then fell by 19.61% to -$37.5 million in 2026.
• Per Business Quant, the three latest ACRS Net Income towards Common Stockholders figures stand at -$37.5 million (Q1 2026), -$31.3 million (Q4 2025), and -$19.2 million (Q3 2025).